{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=71",
    "query": {
      "condition": "Phase I",
      "page": 71
    },
    "page_size": 10
  },
  "pagination": {
    "page": 71,
    "page_size": 10,
    "total_count": 18752,
    "total_pages": 1876,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=72&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=70&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T14:25:48.352Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01592214",
      "title": "Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Staphylococcal Infection"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "XF-73 in 2% Klucel gel",
          "type": "DRUG"
        },
        {
          "name": "XF-73 in 4% Klucel gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 48,
      "start_date": "2012-08",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2016-09-05",
      "last_synced_at": "2026-11-12T14:25:48.352Z",
      "location_count": 2,
      "location_summary": "Anaheim, California • Cleveland, Ohio",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01592214"
    },
    {
      "nct_id": "NCT03348514",
      "title": "Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "CPX-POM - 30 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "CPX-POM - 60 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "CPX-POM - 120 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "CPX-POM - 240 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "CPX-POM - 360 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "CPX-POM - 600 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "CPX-POM - 900 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "CPX-POM - 1200 mg/m^2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CicloMed LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2018-01-15",
      "completion_date": "2020-05-31",
      "has_results": true,
      "last_update_posted_date": "2021-12-03",
      "last_synced_at": "2026-11-12T14:25:48.352Z",
      "location_count": 5,
      "location_summary": "Denver, Colorado • Sarasota, Florida • Kansas City, Kansas + 2 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03348514"
    },
    {
      "nct_id": "NCT02342067",
      "title": "Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Cenicriviroc",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tobira Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2014-12",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2015-05-12",
      "last_synced_at": "2026-11-12T14:25:48.352Z",
      "location_count": 1,
      "location_summary": "Lakewood, Colorado",
      "locations": [
        {
          "city": "Lakewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02342067"
    },
    {
      "nct_id": "NCT04674709",
      "title": "Evaluation of the Safety and Pharmacokinetics of Oleander 4X in Healthy Volunteers",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Flu-like Symptoms"
      ],
      "interventions": [
        {
          "name": "Oleander 4X - single",
          "type": "DRUG"
        },
        {
          "name": "Oleander 4X - double",
          "type": "DRUG"
        },
        {
          "name": "Oleander 4X - quadruple",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avila Herbals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 75,
      "start_date": "2020-11-24",
      "completion_date": "2021-01-15",
      "has_results": false,
      "last_update_posted_date": "2020-12-21",
      "last_synced_at": "2026-11-12T14:25:48.352Z",
      "location_count": 1,
      "location_summary": "Roanoke, Virginia",
      "locations": [
        {
          "city": "Roanoke",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04674709"
    },
    {
      "nct_id": "NCT03485014",
      "title": "Study in Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Postoperative Pain Management"
      ],
      "interventions": [
        {
          "name": "Exparel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pacira Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "12 Years to 16 Years"
      },
      "enrollment_count": 15,
      "start_date": "2018-04-10",
      "completion_date": "2019-02-12",
      "has_results": false,
      "last_update_posted_date": "2023-08-02",
      "last_synced_at": "2026-11-12T14:25:48.352Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03485014"
    },
    {
      "nct_id": "NCT00002204",
      "title": "A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections",
        "HIV Seronegativity"
      ],
      "interventions": [
        {
          "name": "HIV p24/MF59 Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Chiron Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 40,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-12T14:25:48.352Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002204"
    },
    {
      "nct_id": "NCT01755247",
      "title": "A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Topical Gel Vehicle",
          "type": "DRUG"
        },
        {
          "name": "8% NVN1000 Topical Gel",
          "type": "DRUG"
        },
        {
          "name": "8% NVN1000 Topical Gel and moisturizer",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novan, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2012-11",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2019-09-10",
      "last_synced_at": "2026-11-12T14:25:48.352Z",
      "location_count": 1,
      "location_summary": "Broomall, Pennsylvania",
      "locations": [
        {
          "city": "Broomall",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01755247"
    },
    {
      "nct_id": "NCT04266912",
      "title": "Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Malignant Solid Neoplasm",
        "Refractory Malignant Solid Neoplasm",
        "Unresectable Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Berzosertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2020-03-17",
      "completion_date": "2027-01-30",
      "has_results": true,
      "last_update_posted_date": "2026-11-10",
      "last_synced_at": "2026-11-12T14:25:48.352Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04266912"
    },
    {
      "nct_id": "NCT01011530",
      "title": "Dose Escalation Study of MLN4924 in Adults With Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "MLN4924",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2009-12",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2013-07-16",
      "last_synced_at": "2026-11-12T14:25:48.352Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01011530"
    },
    {
      "nct_id": "NCT06327100",
      "title": "Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Primary Myelofibrosis",
        "Post-polycythemia Vera Myelofibrosis",
        "Post-Essential Thrombocytosis Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Tasquinimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2024-08-01",
      "completion_date": "2031-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-11-12T14:25:48.352Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06327100"
    }
  ]
}